Youe‐Kong Shue - Concepedia

Concepedia

Author

Youe‐Kong Shue

Edimer Pharmaceuticals (United States)

Also Known As

Shue, Youe-Kong, Y K Shue, Y. K. SHUE, Y. K. Shue, Y. SHUE, Y.-K. Shue, Y.K. Shue, Y.‐K. SHUE, Youe-Kong Shue, Youe-kong Shue

41

Publications

2.7K

Citations

17

H-Index

52

Concepts

All Affiliations

Edimer Pharmaceuticals (United States)University of Calgary WellStar Health System Cubist Pharmaceuticals (United States)Abbott (United Kingdom)

YS

About

Youe‐Kong Shue is an author at Edimer Pharmaceuticals (United States) specializing in biochemistry, pharmacology, and medicine.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	441
2	Engineering	6	6	198
3	Natural Sciences	6	6	153
4	Arts	1	1	26
5	Health Sciences	1	1	20

Youe‐Kong Shue

×

20

Publications

2.7K

Citations

17

H-Index

	Year	Citations
Fidaxomicin versus Vancomycin for <i>Clostridium difficile</i> Infection Thomas Louie, Mark A. Miller, Kathleen M. Mullane, New England Journal of Medicine	2011	1.6K
Efficacy of Fidaxomicin Versus Vancomycin as Therapy for Clostridium difficile Infection in Individuals Taking Concomitant Antibiotics for Other Concurrent Infections Kathleen M. Mullane, Mark A. Miller, Karl Heinz Weiss, Clinical Infectious Diseases	2011	236
Development of Globo-H Cancer Vaccine Samuel J. Danishefsky, Youe‐Kong Shue, Michael N. Chang, Accounts of Chemical Research VaccinationVaccine DevelopmentGlobo-h Cancer VaccineImmunologyGlycoimmunology	2015	218
Safety, Tolerance, and Pharmacokinetic Studies of OPT-80 in Healthy Volunteers following Single and Multiple Oral Doses Youe‐Kong Shue, P.S. Sears, S. Shangle, Antimicrobial Agents and Chemotherapy	2008	91
Effect of Age on Treatment Outcomes in <i> <scp>C</scp> lostridium difficile </i> Infection Thomas Louie, Mark A. Miller, Derrick W. Crook, Journal of the American Geriatrics Society	2013	81
Synthesis of ergot alkaloids from tryptophan Julius Rebek, Dar‐Fu Tai, Youe‐Kong Shue Journal of the American Chemical Society Molecular SciencesEngineeringErgot AlkaloidsBiochemistryAltmetric Attention Score	1984	74
Novel Structures Derived from 2-[[(2-Pyridyl)methyl]thio]-1<i>H</i>-benzimidazole as Anti-<i>Helicobacter </i><i>p</i><i>ylori </i>Agents, Part 2 Daniel R. Carcanague, Youe‐Kong Shue, Mark A. Wuonola, Journal of Medicinal Chemistry Prototype Carbamate 12AHeterocycle ChemistryChemical BiologyPharmaceutical ChemistryDrug Resistance	2002	74
Typing and susceptibility of bacterial isolates from the fidaxomicin (OPT-80) phase II study for C. difficile infection Diane M. Citron, Farah Babakhani, Ellie J. C. Goldstein, Anaerobe Medical MicrobiologyPathogenic MicrobiologyAntimicrobial SusceptibilityPhase Ii StudyPathogen Characterization	2009	49
Total synthesis of rugulovasines J. Rebek, Youe‐Kong Shue Journal of the American Chemical Society AltmetricsMolecular SciencesEngineeringInformationAltmetric Attention Score	1980	37
An efficient entry to new sugar modified ketolide antibiotics Alex Romero, Chang‐Hsing Liang, Yu-Hung Chiu, Tetrahedron Letters MedicineNew SugarAntimicrobial ChemotherapyPharmacologyPharmaceutical Chemistry	2005	35

Page 1